Skip to main content
OpenTrials
Completed

NCT Number: NCT02687646

Clinical Trial With MSC for Graft Versus Host Disease Treatment

Sequential administration of MSCs obtained from adipose tissue is an effective and safe treatment for acute graft versus host disease refractory to first-line treatment. Furthermore the infusion of these cells produces a biological pattern in patients that relates to the clinical response.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Graft Versus Host Disease

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Clinica Universitaria de Navarra, Av Pio XII ,36, Pamplona, Navarre, Spain

Loading trial locations.

About this study

Multicenter, open, non -controlled clinical trial. It is a phase I-II trial to assess the safety and efficacy of sequential infusion of allogeneic MSCs from adipose tissue, expanded "in vitro" platelet lysate in the treatment of patients undergoing hematopoietic stem cell trasplantation, who have developed a refractory graft versus host disease to first line of treatment.

This is a prospective, multicenter, open to patients undergoing allogeneic transplantation in Spanish hospitals, with one cohort of patients who receive four sequential doses of MSC.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of ≥ grade II Graft Versus Host Disease refractory to first-line treatment.
  • Having been subjected to hematopoietic Stem Cell Transplantation as treatment for malignant blood disorder has been controlled by the transplantation. The source may have been bone marrow cells or peripheral blood (PB) and coming from a family member or unrelated donor.
  • Having been transplanted with myeloablative or non-myeloablative conditioning.
  • normal cardiac function (EF ≥ 40%) without evidence of uncontrolled hypertension, congestive heart failure, angina pectoris or myocardial infarction within 6 months prior to the process
  • Lung function without evidence of severe obstructive or restrictive lung disease.
  • Age between 18 and 65 years.
  • Women of childbearing age considered until one year after the last menstrual period and which have not undergone a surgical sterilization must obtain a negative pregnancy test at the time of inclusion in the study and commit to use a medically approved birth control while on study.
  • normal cardiac function (EF ≥ 40%) without evidence of uncontrolled hypertension, congestive heart failure, angina pectoris or myocardial infarction within 6 months prior to the process.
  • Signature of informed consent -

Exclusion criteria

  • uncontrolled blood disorder by transplantation or progression at the time of inclusion.
  • bacterial, viral, fungal or is not being controlled.
  • Any circumstance that the proposed trial dissuade medical treatment. Pregnancy, lactation or refusal to use safe contraceptive measures.
  • Patients who are currently participating or have completed their participation in a clinical trial in less than 3 months or who have participated in a clinical trial of Advanced Therapies at any previous time period.
  • Patients who are currently participating or have completed their participation in a clinical trial in a period shorter than 3 months or who have participated in a clinical trial of Advanced Therapies at any previous time.
  • positive serology for Hepatitis B , Hepatitis C and AIDS Virus. -

Treatment and study plan

Adult Allogeneic Mesenchymal cells from adipose tissue.

Drug

Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.

Subjects will receive four sequential IV dose of Mesenchymal stem cells.

Sequential doses:

Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg

Other names: MSC for the treatment of graft -versus -host disease

Primary outcomes

  1. Safety measured by incidence of serious adverse events

    Time frame: 2 years

    Safety will be measured in terms of:

    Incidence of Serious Adverse Events after at the time of the infusion of study drug or during follow-up.

Secondary outcomes

  1. Effectiveness measured by answer of refractory acute graft disease against host to first-line treatment

    Time frame: 2 years

    Effectiveness will be measured in terms of:

    Answer of refractory acute graft disease against host to first-line treatment

Sponsors and collaborators

Lead sponsor

Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud

Other

Collaborators

  • Andalusian Initiative for Advanced Therapies

Registry information

Official study title

Clinical Trial Phase I / II Graft Versus Host Disease Treatment Refractory to First-line Therapy With Sequential Infusion of Mesenchymal Cells Allogeneic Expanded Adipose Tissue in Vitro

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
Feb 22, 2016
Registry last updated
Oct 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.